46th Interscience Conference on Antiretroviral Agents and Chemotherapy (ICAAC), 27-30 September 2006, San Francisco

7 October 2006. Related: Conference reports, Conference index, ICAAC 46th San Francisco 2006.

This US-based annual conference has generally reversed its trend for reduced HIV coverage, by including several important studies of new drugs.

Reports from this meeting

• MK-0518 demonstrates potent efficacy in patients with triple-class resistant virus: 24 week results

• Lipid profile of integrase inhibitor MK-0518: 24 week results compared to efavirenz in treatment naive patients

• Cell studies predict cross-resistance among integrase inhibitors

• HIV may use different coreceptors in blood and brain

• Critical interactions between darunavir (TMC114), lopinavir, Viagra, and oral contraceptives

• NRTI elvucitabine active against HIV in a 7-day monotherapy study

• Efavirenz/tenofovir fails as 2-drug maintenance regimen

• Nucleoside inhibitor MK-0608 mediates suppression of HCV replication for >30 days in chronically infected chimpanzees